R Stock Recent News

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R), a leader in supply chain, dedicated transportation, and fleet management solutions, today provided details regarding its conference call scheduled for Thursday, October 24, 2024 at 11:00 a.m. Eastern Time. During the call, management will review third quarter 2024 results. The call will be webcast over the internet. What: Ryder System, Inc. Third Quarter 2024 Earnings Conference Call   Who: Chairman and Chief Executive Officer Robert Sanchez.

New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine Procedures BELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leading global medical technology company focused on the treatment of spinal disorders, is excited to announce the launch of the Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries. Now available to surgeons across the United States through Xtant's commercial channels.

J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just - Evotec Biologics' J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions HAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / September 20, 2024 / Just - Evotec Biologics, the biologics segment of Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO), today celebrated the Grand Opening of its J.POD® biologics development and manufacturing facility located on Evotec's Campus Curie in Toulouse, France. The J.POD® facility in Toulouse, the second of its kind and the first in Europe, utilizes Just - Evotec Biologics' adaptable J.POD® technology to provide essential clinical and commercial biologics manufacturing capacity.

TORONTO, ON / ACCESSWIRE / September 19, 2024 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 10,000,000 share purchase warrants ("Warrants") from September 22, 2024 to September 22, 2027. The Warrants were issued on September 22, 2022, pursuant to a private placement involving the issuance of 10,000,000 units of the Company.

~ New SI Joint Fixation Device Offers a 30% Reduction in Implant Size Providing Physicians Choices for Varying Anatomy and Treatment Strategies with the Catamaran Technology ~ ~ The SE System Can Also Be Utilized with a Manual Drilling Option During Implant Preparation~ LOS GATOS, CA / ACCESSWIRE / September 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced preparation for the initial alpha launch of the Company's new Catamaran SE SI Joint Fusion System targeted for the beginning of Q4. The Catamaran SE Fixation Device extends the line of implant offerings for physicians preferring a smaller Catamaran implant when performing a SI joint fusion procedure.

Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial study to determine consumer comprehension of the messaging in its App Technology ("App Comp"), which has unique differences from the current Drug Facts Label ("DFL"). Of the 31 objectives, 29 scored >90% comprehension Point Estimate ("PE"), 30 scored >86.7% comprehension PE, and all scored > 80% comprehension PE.

Atlantic Power & Infrastructure Corp. (OTC PINK:AWSL) continues to gain momentum with the increasing adoption of its Flexi®-Pave technology by educational institutions across the country. CLEARWATER, FL & TAMPA BAY, FL / ACCESSWIRE / September 11, 2024 / Atlantic Power & Infrastructure Corp. (OTC PINK:AWSL) continues to gain momentum with the increasing adoption of its Flexi®-Pave technology by educational institutions across the country.

NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE:R). The settlement provides for a fund of $45,000,000 to benefit class members.

Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under "fed" conditions DehydraTECH-treated Rybelsus® does absorb through a mouth-melt product format KELOWNA, BC / ACCESSWIRE / August 29, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that tolerability and additional pharmacokinetic ("PK") results from human pilot study #2, GLP-1-H24-2, (the "Study") have been received.

TORONTO, ON / ACCESSWIRE / August 28, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation and or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation, Rutherrin®, has demonstrated an ability to provide a significant enhancement of Cisplatin efficacy in chemotherapy resistant Non-Small Cell Lung Cancer ("NSCLC") in a preclinical animal model. Theralase® recently press released its latest research, using the well-established Lewis Lung Cancer ("LLC1") orthotopic model, representing NSCLC.